CORESTEMCHEMON Inc. (KOSDAQ:166480)

Market Cap	176.33B
Revenue (ttm)	20.13B -30.3%
Net Income	-12.92B
EPS	-491.98
Shares Out	44.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,607,345
Average Volume	1,429,021
Open	3,690.00
Previous Close	3,665.00
Day's Range	3,410.00 - 3,910.00
52-Week Range	1,014.00 - 4,310.00
Beta	0.66
RSI	87.92
Earnings Date	Mar 20, 2026

About CORESTEMCHEMON

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company has a strategic partnership ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 36
• Stock Exchange: KOSDAQ
• Ticker Symbol: 166480

Financial Performance

In 2024, CORESTEMCHEMON's revenue was 28.76 billion, a decrease of -14.54% compared to the previous year's 33.66 billion. Losses were -26.25 billion, 48.6% more than in 2023.